NEW YORK (GenomeWeb) – Bioinformatics firm Omicia said today that Laboratory Corporation of America will use its clinical next-generation sequencing interpretation software as part of its clinical trials sequencing services offering.
According to Omicia, its analysis software will provide customers of LabCorp's testing services menu with a comprehensive suite of tools and services that they can use to incorporate and integrate genomic data into clinical trials. The suite includes tools for annotating and analyzing variants and generating customized clinical reports across a broad range of disease states and clinical trial designs.
The combined offering helps address the increasing "demand for well annotated and meaningful biomarker data to guide clinical trial design and execution," Mike Aicher, Omicia's CEO, said in a statement.
Financial and other terms of the agreement were not disclosed.